1 2 "Wegovy Product information"
Provider Comparisons Compare Hims, Ro, and Noom Med for GLP-1 weight loss
Salas-Whalen, author of the book, Weightless: A Doctors Guide to GLP-1 Medications, Sustainable Weight Loss, and the Health You Deserve ," cited estimates that half of the world population will have obesity by 2030, which has implications on everything from rates of type 2 diabetes to certain cancers
So one ongoing question in the field is to identify the phenotypes, the subgroups of people who may be more responsive to these medications. Other challenges include patient adherence to treatment, which 20 percent of physicians cited as a challenge, and side effect management, which 18 percent of physicians cited as a challenge